sanostem

  • 1615 South Street, 93304

Ischemic Stroke

Ischemic Stroke

Chronic Ischemic Stroke

Nearly 800,000 people have a stroke in the US alone each year. Stroke is the third leading cause of mortality in the United States, accounting for almost 137,000 of those deaths. Blood clots are the cause of ischemic strokes, which account for 87% of all strokes.  There are 101 million people suffering from the after effects of an ischemic stroke.

SanoStem completed and published a Phase I/IIa clinical trial to evaluate the safety and effectiveness of employing adult bone-marrow derived mesenchymal stem cells in ischemic stroke. There was clinically significant recovery in all 4 efficacy endpoints: NIH Stroke Scale, Barthel Index, Mini-Mental Status Exam and Geriatric Depression Scale.

FDA has approved a Phase IIb/III clinical trial to further study the effects of SanoMSC in ischemic stroke. This study is being actively pursued in Kazakhstan, India and Australia.

The chief investigator, Michael Levy MD led the Phase I/IIa clinical trial at the University of California, San Diego, Dr. Nabil Dib MD oversaw the study at Gilbert Hospital, and Steven Cramer MD oversaw the study at University of California, Irvine.

Ischemic Stroke

Nearly 800,000 people have a stroke in the US alone each year. Stroke is the third leading cause of mortality in the United States, accounting for almost 137,000 of those deaths. Blood clots are the cause of ischemic strokes, which account for 87% of all strokes. In order to evaluate the safety and effectiveness of employing adult bone-marrow derived mesenchymal stem cells for ischemic stroke patients, Stemedica has finished a Phase I/IIA clinical trial.
The chief investigator, Michael Levy, M.D., led the clinical trial at the University of California, San Diego. Dr. Nabil Dib, M.D., oversaw Gilbert Hospital, and Steven Cramer, M.D., oversaw the University of California Irvine.
Scroll to Top